Pharming Group N.V. (PHARM: NA) (OTC: PHGUF) Attends 31st Annual ROTH Conference
Pharming Group N.V. (PHARM: NA) (OTC: PHGUF) is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. The company develops innovative products for the treatment of unmet medical needs. Pharming’s lead product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (“HAE”) attacks in patients in Europe, the US, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization. For more information, visit the company's website at www.pharming.com.…







